Brett P. Monia - Jan 26, 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Chief Executive Officer, Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Stock symbol
IONS
Transactions as of
Jan 26, 2022
Transactions value $
-$252,526
Form type
4
Date filed
1/28/2022, 04:58 PM
Previous filing
Jan 20, 2022
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Award $0 +2.19K +2.73% $0.00 82.4K Jan 26, 2022 Direct F1
transaction IONS Common Stock Award $0 +14K +16.99% $0.00 96.4K Jan 26, 2022 Direct F2
transaction IONS Common Stock Tax liability -$253K -8.03K -8.33% $31.44 88.4K Jan 26, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 58.06% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F2 Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 81.37% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.
F3 Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.